Primary Philadelphia-chromosome positive leukemia cells from chronic myelogenous leukemia (CML) research hub

Comparative Bioavailability of Nilotinib 200 mg Hard Capsules: A Single-Dose, Open-Label, Randomized, Four-Sequence, Four-Treatment, Four-Period Crossover Pilot Study in Healthy Subjects.

This study is comparing different versions of a medicine called Nilotinib to see if they work the same way in the body. It helps us understand if new versions of medicines are as effective as existing ones, for conditions like a type of leukaemia. This is an early-stage study in healthy volunteers.